News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MycoLogics, Inc. Moves Closer Towards The Discovery Of An Apergillus Fumigatus Vaccine



10/19/2005 5:10:27 PM

MycoLogics, Inc., an innovative biotechnology company specializing in the development of novel antifungal drugs and therapeutic and prophylactic vaccines against human fungal and parasitic pathogens, today announced award of a Phase I SBIR grant by the Department of Health and Human Services to derive a novel vaccine against Aspergillus fumigatus, a ubiquitous spore-bearing fungus that causes multiple diseases in humans. These diseases include allergic asthma, aspergillomas, and invasive pulmonary disease of those with predisposing underlying conditions.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES